Zacks Research Forecasts Reduced Earnings for Henry Schein

Henry Schein, Inc. (NASDAQ:HSIC) – Research analysts at Zacks Research cut their Q1 2027 earnings estimates for Henry Schein in a note issued to investors on Tuesday, October 14th. Zacks Research analyst Team now expects that the company will post earnings per share of $1.38 for the quarter, down from their previous estimate of $1.39. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, August 5th. The company reported $1.10 earnings per share for the quarter, missing the consensus estimate of $1.19 by ($0.09). The company had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.22 billion. Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The business’s revenue was up 3.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.23 earnings per share. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS.

Several other equities analysts have also recently weighed in on HSIC. Wall Street Zen cut shares of Henry Schein from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. UBS Group dropped their price objective on shares of Henry Schein from $75.00 to $70.00 and set a “neutral” rating for the company in a research note on Wednesday, August 6th. Leerink Partners set a $75.00 price objective on shares of Henry Schein in a research note on Monday, July 14th. JPMorgan Chase & Co. dropped their price objective on shares of Henry Schein from $80.00 to $76.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th. Finally, Robert W. Baird reissued a “neutral” rating and issued a $72.00 price objective (down from $82.00) on shares of Henry Schein in a research note on Monday, July 14th. Five analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, Henry Schein has a consensus rating of “Hold” and an average target price of $76.67.

Henry Schein Stock Performance

HSIC opened at $62.03 on Thursday. The stock has a market capitalization of $7.52 billion, a price-to-earnings ratio of 20.01, a PEG ratio of 2.09 and a beta of 0.81. The company has a fifty day moving average of $67.18 and a 200 day moving average of $68.64. Henry Schein has a fifty-two week low of $60.56 and a fifty-two week high of $82.49. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.78 and a current ratio of 1.41.

Hedge Funds Weigh In On Henry Schein

A number of large investors have recently made changes to their positions in HSIC. CYBER HORNET ETFs LLC purchased a new position in shares of Henry Schein during the 2nd quarter worth about $25,000. MUFG Securities EMEA plc purchased a new position in shares of Henry Schein during the 2nd quarter worth about $27,000. Rakuten Securities Inc. purchased a new position in shares of Henry Schein during the 1st quarter worth about $34,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Henry Schein during the 2nd quarter worth about $43,000. Finally, Steph & Co. purchased a new position in shares of Henry Schein during the 2nd quarter worth about $44,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.